Jefferies Group’s Kymera Therapeutics KYMR Stock Holding History

Jefferies Group’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,000	Closed	-$310K	–	1821
2020 Q4	$310K	Buy	+5,000	New	+$244K	﹤0.01%	1272

Other funds holding KYMR

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DIC

Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jefferies Group's KYMR Position: Q1 2021 in Review

Jefferies Group sold out of Kymera Therapeutics (KYMR) in Q1 2021, closing a stake of 5,000 shares — an estimated $310K sold.

Jefferies Group first reported a position in KYMR in Q4 2020 and held it in 1 quarter. The position peaked at $310K in Q4 2020. 97 funds tracked by Wall St. Rank hold KYMR as of Q1 2021.

Jefferies Group reported no remaining Kymera Therapeutics position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 5,000 Kymera Therapeutics shares in Q1 2021, an estimated $310K.
Jefferies Group first reported a position in Kymera Therapeutics in Q4 2020 and held it in 1 quarter.
Jefferies Group's Kymera Therapeutics position peaked at $310K in Q4 2020.
97 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.